GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ARMP
Shares of Armata, a biopharmaceutical company developing bacteriophages to combat infections, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma microbes
Armata Pharmaceuticals is a biotechnology company developing targeted bacteriophage-based therapies for the treatment of antibiotic-resistant infections. We classify it under the Pharmaceuticals (Microbes) category. The chart below shows the dynamics of this promising area of medicine.
Broad Market Index - GURU.Markets
Armata Pharmaceuticals is a biotech company pioneering the development of bacteriophage-based therapies to combat antibiotic-resistant infections. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Armata's performance to assess the sector's prospects.
Change in the price of a company, segment, and market as a whole per day
ARMP - Daily change in the company's share price ARMP
Armata Pharmaceuticals' daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the stock's sensitivity to news about its bacteriophage therapy clinical trials, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Pharma microbes
Armata Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ARMP's performance, which focuses on bacteriophage therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Armata Pharmaceuticals is developing bacteriophage-based therapies to combat antibiotic-resistant infections. This is at the forefront of biotechnology, and the company's shares are driven by research news. Their volatility is part of the overall market flow driven by scientific innovation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ARMP
For Armata Pharmaceuticals, the year-over-year performance is a story of the resurgence of bacteriophage therapy. Its 12-month market capitalization is entirely dependent on clinical trial data for its drugs for the treatment of antibiotic-resistant infections. Success could offer the world a new tool to combat one of the main threats to public health.
Annual dynamics of market capitalization of the market segment - Pharma microbes
Armata Pharmaceuticals, Inc. is a biotechnology company pioneering the development of bacteriophage-based therapies to combat resistant infections. Its stock price is highly volatile, reflecting investor confidence in its breakthrough potential rather than its current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Armata is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its bacteriophage therapy trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ARMP
Armata Pharmaceuticals is developing bacteriophage therapy to combat resistant infections. Its monthly growth is entirely dependent on clinical trial results. Positive data on the effectiveness of its drugs against superbugs could trigger a sharp increase, reflecting the high potential of this technology.
Monthly dynamics of market capitalization of the market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company developing therapies based on bacteriophages—viruses that selectively destroy bacteria. This is a promising alternative to antibiotics. The graph below shows the dynamics of the biotech sector, where combating antibiotic resistance is a global challenge.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Armata Pharmaceuticals fights bacterial infections with bacteriophages—an alternative to antibiotics. This is a breakthrough in medicine. The company's shares are driven by news of clinical trials and successes in the fight against superbugs, and their performance is completely disconnected from overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ARMP
Shares of Armata Pharmaceuticals, a company developing bacteriophages to fight infections, reflect the search for alternatives to antibiotics on a weekly basis. Price movements are a response to clinical trial data that could offer a new weapon against resistant bacteria.
Weekly dynamics of market capitalization of the market segment - Pharma microbes
Armata Pharmaceuticals fights bacterial infections with bacteriophages, the natural enemies of bacteria. They are an alternative to antibiotics. The chart will show whether Armata's share price movements are a reaction to its unique clinical data or reflect general investor sentiment toward the entire superbug sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Armata Pharmaceuticals is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Armata is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are actually influencing its stock price.
Market capitalization of the company, segment and market as a whole
ARMP - Market capitalization of the company ARMP
Armata's market capitalization tells the story of a biotech company reviving the age-old idea of using bacteriophages (bacteria-killing viruses) to fight antibiotic-resistant infections. Its volatile price chart reflects the hope that this approach will become a new weapon in doctors' arsenal.
ARMP - Share of the company's market capitalization ARMP within the market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company pioneering the development of bacteriophage-based therapeutics for the treatment of antibiotic-resistant infections. Its market capitalization reflects the potential of this approach. The chart shows how much the market is betting on the "return" of phage therapy to medicine.
Market capitalization of the market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company reviving the idea of using bacteriophages to combat bacterial infections. The chart below shows the market capitalization of this sector. Its dynamics reflect the growing problem of antibiotic resistance, making Armata's innovative approach particularly relevant.
Market capitalization of all companies included in a broad market index - GURU.Markets
Armata Pharmaceuticals develops therapies based on bacteriophages—viruses that destroy bacteria. Its capitalization is a bet that phages will become an alternative to antibiotics in the fight against superbugs. Its momentum reflects the race for new ways to combat one of the greatest threats to human health.
Book value capitalization of the company, segment and market as a whole
ARMP - Book value capitalization of the company ARMP
Armata Pharmaceuticals' book value is its equity and patents for technology using bacteriophages (viruses that infect bacteria) to combat antibiotic-resistant infections. This is the tangible, scientific foundation for the post-antibiotic era. How has this unique asset changed? The chart below shows its dynamics.
ARMP - Share of the company's book capitalization ARMP within the market segment - Pharma microbes
Armata Pharmaceuticals is developing bacteriophage-based therapies to combat antibiotic-resistant infections. The chart shows the share of its unique laboratory and manufacturing assets, reflecting the physical foundation of this promising technology.
Market segment balance sheet capitalization - Pharma microbes
Armata Pharmaceuticals fights bacterial infections with bacteriophages. This is a science-intensive process. A balance sheet capitalization chart shows that the company's main assets are patents and R&D, not manufacturing plants, which is typical for biotech.
Book value of all companies included in the broad market index - GURU.Markets
Armata Pharmaceuticals fights superbugs with bacteriophages. Its book value is derived from its production capacity for phage cocktails and its laboratory. The chart shows the material foundation on which this technology, an alternative to antibiotics, is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ARMP
Armata Pharma's balance sheet is capital. But the market sees it as a pioneer in the fight against superbugs. The chart shows the "hope factor": a premium for its bacteriophage-based technology, which could become an alternative to antibiotics.
Market to book capitalization ratio in a market segment - Pharma microbes
Armata Pharmaceuticals is developing bacteriophage-based therapies to combat antibiotic-resistant infections. Its value lies in its unique scientific platform. The chart shows how investors view its potential to address one of the most serious healthcare challenges.
Market to book capitalization ratio for the market as a whole
Armata Pharmaceuticals is a biotech company pioneering the development of bacteriophage therapy. It uses viruses (phages) to destroy antibiotic-resistant bacteria. This chart shows the overall valuation, but how does the market value a company offering a solution to one of the most serious threats to global healthcare?
Debts of the company, segment and market as a whole
ARMP - Company debts ARMP
Armata Pharmaceuticals is developing bacteriophage-based therapy as an alternative to antibiotics. This chart shows how the company is funding its research in this revolutionary but high-risk field. It's a financial bet that its approach will become a key solution in the fight against antibiotic-resistant bacteria.
Market segment debts - Pharma microbes
Armata Pharmaceuticals is developing targeted bacteriophage therapy to combat antibiotic-resistant infections. This represents an important alternative to traditional antibiotics. This chart shows how the company is funding its clinical trials in this new and complex area of medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ARMP
Armata Pharmaceuticals is fighting antibiotic-resistant bacteria with bacteriophages. This chart shows how the company is funding its cutting-edge, yet risky, research. Amid the global antibiotic resistance crisis, debt is a tool for developing breakthrough technology that could save lives.
Market segment debt to market segment book capitalization - Pharma microbes
Armata Pharmaceuticals is developing bacteriophage-based therapies to treat antibiotic-resistant infections. This chart shows the overall debt burden in the biotech sector. It helps understand how companies working on antibiotic alternatives finance their unique and risky clinical trials.
Debt to book value of all companies in the market
Armata Pharmaceuticals fights bacterial infections with bacteriophages. This is an alternative to antibiotics that requires extensive clinical trials. The market's total debt burden chart doesn't reflect the company's specifics, as its funding relies entirely on venture capital and success in fighting superbugs, not loans.
P/E of the company, segment and market as a whole
P/E - ARMP
This chart for Armata Pharmaceuticals, a company developing bacteriophage therapy to combat antibiotic-resistant infections, shows the valuation of its approach. The multiple reflects investors' belief that phages will become a vital tool in medicine, solving one of the most pressing problems in modern healthcare.
P/E of the market segment - Pharma microbes
Armata's focus on fighting bacterial infections is a significant area. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Armata, with its bacteriophage technology, is being evaluated as an alternative to antibiotics, a huge but risky potential market.
P/E of the market as a whole
Armata Pharmaceuticals is developing targeted therapy based on bacteriophages—viruses that selectively destroy bacteria. It offers a promising alternative to antibiotics in the fight against superbugs. This biotech sentiment chart helps understand how the market is pricing this resurgent, yet still experimental, technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ARMP
Armata Pharmaceuticals is a biotech company developing bacteriophage-based therapies for the treatment of antibiotic-resistant bacterial infections. This chart reflects expectations for its approach to combating one of the world's leading health threats. The trend is an assessment of the success of its clinical programs.
%20P%2FE%20ARMP&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ARMP&v=1772599542112 "Chart of the company's future (projected) P/E ARMP")
Future (projected) P/E of the market segment - Pharma microbes
Armata Pharmaceuticals is developing targeted bacteriophage-based therapy for the treatment of antibiotic-resistant infections. This chart shows profitability expectations for the sector. It helps understand how highly the market values the potential of this alternative approach to combating superbugs, one of the major threats to healthcare.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-microbes&v=1772599542113 "Future (projected) P/E graph of the market segment - Pharma microbes")
Future (projected) P/E of the market as a whole
Armata Pharmaceuticals, Inc. is a biotech company developing bacteriophage-based therapies for the treatment of antibiotic-resistant infections. This chart shows investor risk appetite. For a company offering an alternative to antibiotics, it reflects the market's willingness to invest in innovative approaches to combating one of the world's leading health threats.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772599542113 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ARMP
Armata Pharmaceuticals, Inc. is a biotechnology company developing bacteriophage-based therapies for the treatment of antibiotic-resistant infections. The financial outcome illustrated in this chart is comprised of clinical trial costs. It illustrates the cost of reviving and modernizing an old approach to combat one of the major health threats.
Profit of companies in the market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company developing therapies based on bacteriophages—viruses that selectively destroy bacteria. This approach offers a promising alternative to antibiotics. This chart illustrates how new approaches to fighting infections could address the global problem of resistance and create enormous profit potential.
Overall market profit
Armata Pharmaceuticals is developing bacteriophage therapy—an alternative to antibiotics for fighting resistant infections. This is a critically important but complex area of research. The company's success depends on the results of clinical trials. This overall market return chart provides the backdrop against which investors make funding decisions for such breakthrough medical projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ARMP
Armata Pharmaceuticals is a biotech company developing bacteriophage-based therapies for the treatment of antibiotic-resistant infections. The profit/loss projections in this chart represent a bet that this technology will be the solution to a growing global problem.
%20profit%20of%20the%20company%20ARMP&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ARMP&v=1772599542134 "Graph of future (projected) profit of the company ARMP")
Future (predicted) profit of companies in the market segment - Pharma microbes
Armata Pharmaceuticals is developing targeted bacteriophage therapy for the treatment of antibiotic-resistant infections. This is a revival of an old approach at a new technological level. This chart shows the revenue forecast for the microbial pharmaceutical sector, allowing us to assess how Armata can address one of the most serious challenges in modern healthcare.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-microbes&v=1772599542135 "Graph of future (predicted) profits of companies in a market segment - Pharma microbes")
Future (predicted) profit of the market as a whole
Armata Pharmaceuticals is a biotech company developing bacteriophage therapy to combat antibiotic-resistant infections. Its success depends on the results of clinical trials. This graph, reflecting market sentiment, affects the availability of funding for such innovative medical approaches.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772599542136 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ARMP
Armata Pharmaceuticals is developing a therapy based on bacteriophages—viruses that kill bacteria—to combat antibiotic-resistant infections. This chart shows how investors view the potential of this alternative approach. The valuation is a bet on success in tackling one of the leading health threats.
P/S market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company developing bacteriophage-based therapies (viruses that infect bacteria) to treat antibiotic-resistant infections. This chart shows the industry average price-to-sales ratio, reflecting investor expectations for this promising approach to combating one of the world's leading health threats.
P/S of the market as a whole
Armata Pharmaceuticals is a biotechnology company developing therapeutics based on bacteriophages (viruses that infect bacteria) to treat antibiotic-resistant infections. This chart helps understand how the market is evaluating innovative approaches to combating one of the main threats to global health.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ARMP
Armata Pharmaceuticals is developing bacteriophage-based therapies for the treatment of antibiotic-resistant infections. This chart shows the company's valuation relative to its projected future sales. It reflects investor expectations that phage therapy will become a key tool in the fight against superbugs.
%20P%2FS%20ARMP&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ARMP&v=1772599542152 "The graph of the company's future (projected) P/S ARMP")
Future (projected) P/S of the market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company developing targeted bacteriophage-based therapies for the treatment of antibiotic-resistant infections. These therapies offer a promising alternative to traditional antibiotics. This chart reflects investor expectations for its scientific platform and potential future revenue.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-microbes&v=1772599542154 "Future (projected) P/S market segment graph - Pharma microbes")
Future (projected) P/S of the market as a whole
Armata Pharmaceuticals is a biotech company developing bacteriophage-based therapies to combat antibiotic-resistant infections. Its future depends on the success of clinical trials. This general expectations chart for ARMP is not a direct driver. The company is working to address one of the most pressing healthcare challenges, independent of economics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772599542155 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ARMP
This chart illustrates the financial trajectory of a biotech company. For Armata Pharmaceuticals, which is focused on developing bacteriophage therapy to combat antibiotic-resistant infections, it reflects funds received from investors and grants to fund clinical trials.
Sales of companies in the market segment - Pharma microbes
Armata Pharmaceuticals, Inc. is developing bacteriophage-based therapies to treat antibiotic-resistant infections. This is a revival of an old technology to combat a new threat. This graph shows revenue in the pharmaceutical sector. Armata's success could offer a vital alternative to antibiotics and create an entirely new market.
Overall market sales
Armata Pharmaceuticals is developing therapeutics based on bacteriophages—viruses that kill bacteria. This is a promising alternative to antibiotics. The company's success reflects its search for new solutions to combat antibiotic resistance, one of the main threats to global health. This is at the forefront of medical science.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ARMP
Armata Pharmaceuticals is developing bacteriophage-based therapies (viruses that infect bacteria) to combat antibiotic-resistant infections. Future sales projections depend on the success of this alternative antibacterial strategy.
%20sales%20of%20the%20company%20ARMP&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ARMP&v=1772599542157 "Schedule of future (projected) sales of the company ARMP")
Future (projected) sales of companies in the market segment - Pharma microbes
Armata Pharmaceuticals, Inc. develops bacteriophage-based therapeutics to combat antibiotic-resistant infections. The forecast for the antimicrobial pharmaceutical sector reveals a pressing need. The graph reflects the world's urgent need for alternatives to traditional antibiotics, creating enormous potential for phage therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-microbes&v=1772599542168 "Schedule of future (projected) sales of companies in the market segment - Pharma microbes")
Future (projected) sales of the market as a whole
Armata Pharmaceuticals is developing bacteriophage therapy to combat antibiotic-resistant infections. The company's success depends on the results of clinical trials. The need for new treatments for infections is enormous and is not dependent on economic cycles. This timeline is important only in terms of the overall investment climate for the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772599542171 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ARMP
Armata Pharmaceuticals is a biotech company developing bacteriophage-based therapies to combat antibiotic-resistant bacterial infections. Being in clinical trials, it incurs high R&D costs. This chart shows the "cost of innovation"—the amount of investment in developing a new approach to treating infections.
Market segment marginality - Pharma microbes
Armata Pharmaceuticals is a biotechnology company developing bacteriophage-based therapies for the treatment of antibiotic-resistant infections. Its profitability depends on the success of this alternative treatment approach. This metric reflects its operational structure and investment in research compared to traditional pharmaceutical companies.
Market marginality as a whole
Armata Pharmaceuticals, Inc. is a biotech company developing bacteriophage-based therapies for the treatment of antibiotic-resistant infections. This chart shows the company's overall profit margin. In this context, Armata is betting on an alternative to antibiotics. The company is unprofitable, and its future depends on the success of this innovative, but not yet widely proven, technology.
Employees in the company, segment and market as a whole
Number of employees in the company ARMP
Armata Pharmaceuticals is developing bacteriophage-based therapies to combat antibiotic-resistant infections. Its team of scientists is key to success in this cutting-edge field. Growth on this chart will be directly related to the progress of its drugs in clinical trials and the expansion of its manufacturing capabilities for creating phage cocktails.
Share of the company's employees ARMP within the market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company at the forefront of developing bacteriophage therapy for antibiotic-resistant infections. This chart highlights its scientific leadership, reflecting the percentage of microbiologists and infectious disease specialists working on this resurgent approach to combating superbugs that Armata is attracting.
Number of employees in the market segment - Pharma microbes
Armata Pharmaceuticals is developing bacteriophage therapy to combat antibiotic-resistant bacterial infections. This graph illustrates the search for alternatives to traditional antibiotics. The growth of the research team reflects the global concern about superinfections and the hope that phages will become a new weapon in this fight.
Number of employees in the market as a whole
Armata Pharmaceuticals is a biotech company developing bacteriophage-based therapies to combat antibiotic-resistant infections. This is a critically important, yet still experimental, area of medicine. Their development depends on scientific breakthroughs, not the labor market, as this chart illustrates.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ARMP (ARMP)
Armata Pharmaceuticals is a biotech company developing bacteriophage-based therapies to combat antibiotic-resistant infections. This represents a significant alternative to traditional approaches. This chart shows how the market values this potential solution to a global problem. The high market capitalization per employee reflects the value of their unique platform and phage library.
%20of%20the%20company%20ARMP%20(ARMP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ARMP-ARMP&v=1772599542206 "Chart of market capitalization per employee (in thousands of dollars) of the company ARMP (ARMP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma microbes
Armata Pharmaceuticals is developing bacteriophage therapy to combat antibiotic-resistant infections. This is a cutting-edge field of biotechnology. This chart shows how investors view the potential of this antibiotic alternative. The high cost per employee reflects their faith in the scientific breakthroughs the company's team can achieve.
%20by%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-microbes&v=1772599542210 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma microbes")
Market capitalization per employee (in thousands of dollars) for the overall market
Armata Pharmaceuticals is developing targeted bacteriophage therapy for the treatment of antibiotic-resistant infections. This chart reflects the employee's high praise, as its technology could offer a solution to one of the most serious threats to global healthcare.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772599542214 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ARMP (ARMP)
Armata Pharmaceuticals is a biotech company developing bacteriophage-based therapies (viruses that kill bacteria) to treat antibiotic-resistant infections. This is an R&D alternative to antibiotics. This is a negative indicator. It shows how much the company spends on each scientist to develop and test this "live" therapy.
%20Chart%20ARMP%20(ARMP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ARMP-ARMP&v=1772599542220 "Company Profit Per Employee (in thousands of dollars) Chart ARMP (ARMP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma microbes
Armata Pharmaceuticals (ARMP) is a biotech company developing bacteriophage-based therapies to combat resistant infections. As with many biotechs, this graph is a guide to the future. Currently, profitability is negative. ARMP's success will depend on whether its team can prove the efficacy of this innovative therapy.
%20in%20the%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-microbes&v=1772599542221 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma microbes")
Profit per employee (in thousands of dollars) for the market as a whole
Armata Pharmaceuticals (ARMP) fights bacterial infections with bacteriophages, an alternative to antibiotics. It's a clinical-stage biotech company. Negative profit per employee is the norm. The chart shows the "cost" of the team of scientists working on this promising, but not yet approved, technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772599542228 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ARMP (ARMP)
Armata Pharmaceuticals is developing bacteriophage therapy to combat antibiotic-resistant infections. This chart reflects its status as an R&D company. Lack of revenue is normal. In the future, this metric will become a measure of the commercial success of its breakthrough technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ARMP-ARMP&v=1772599542235 "Sales chart per company employee ARMP (ARMP)")
Sales per employee in the market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company specializing in bacteriophages—bacteria-killing viruses—to combat antibiotic-resistant infections. During the R&D phase, this metric reflects how effectively their research team generates revenue (e.g., from grants) by promoting this alternative to antibiotics.
Sales per employee for the market as a whole
Armata Pharmaceuticals is a biotech company specializing in the development of phage therapy (using bacteriophages) to treat antibiotic-resistant infections. It's an R&D company. This chart shows revenue per employee. Predictably, it's zero or very low (from grants), as the entire research staff is focused on drug development.
Short shares by company, segment and market as a whole
Shares shorted by company ARMP (ARMP)
Armata Pharmaceuticals is developing a therapy based on bacteriophages—viruses that selectively destroy bacteria. It is being considered as an alternative to antibiotics. This chart shows bearish bets. Bears doubt this technology will prove effective in rigorous clinical trials or that its production will be commercially viable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ARMP-ARMP&v=1772599542245 "Short Shares Chart for the Company ARMP (ARMP)")
Shares shorted by market segment - Pharma microbes
Armata Pharmaceuticals is developing bacteriophage therapy to combat antibiotic-resistant bacterial infections. This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or funding issues.
Shares shorted by the overall market
Armata (ARMP) is a clinical-stage biotech. Its value reflects the hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ARMP (ARMP)
Armata Pharmaceuticals is developing bacteriophage therapy against resistant infections. The stock is highly speculative. This chart could soar above 70 on positive trial data. Oversold territory (<30) often reflects setbacks, delays, or concerns about funding for this new technology.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ARMP-ARMP&v=1772599542259 "RSI 14 indicator chart for the company's stock ARMP (ARMP)")
RSI 14 Market Segment - Pharma microbes
Armata (ARMP) is a superbug "killer." They're *not* antibiotics, but *phages*—"viruses" that *specifically* "eat" *resistant* bacteria. The "Pharma" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is ARMP's growth due to their R&D, or is *the entire* biotech sector "overheated?"
RSI 14 for the overall market
For Armata Pharmaceuticals, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ARMP (ARMP)
Armata Pharmaceuticals is a biotech company developing bacteriophages (bacteria-killing viruses) to treat antibiotic-resistant infections. This chart shows the average target price. Analysts' forecasts are based on clinical data and the potential of this alternative to traditional antibiotics.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ARMP-ARMP&v=1772599542272 "A chart showing analyst consensus forecasts for the expected stock price. ARMP (ARMP)")
The difference between the consensus estimate and the actual stock price ARMP (ARMP)
Armata is a biotech company reviving "phage therapy"—the use of viruses (bacteriophages) to destroy antibiotic-resistant superbugs. This chart shows how far the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this "post-antibiotic" technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ARMP-ARMP&v=1772599542281 "A chart showing the difference between the consensus forecast and the actual stock price. ARMP (ARMP)")
Analyst consensus forecast for stock prices by market segment - Pharma microbes
Armata Pharmaceuticals is a biotech company reviving an "old" technology: the use of bacteriophages (bacteria-killing viruses) to combat antibiotic-resistant superbugs. This chart reflects general expectations for the pharmaceutical sector, showing whether experts believe in phage therapy.
Analysts' consensus forecast for the overall market share price
Armata Pharmaceuticals (ARMP) is a company reviving "phage therapy." They use "good" viruses (bacteriophages) to destroy antibiotic-resistant superbugs. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough but complex R&D projects in the fight against superbugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ARMP
Armata Pharmaceuticals is a superbug killer. They are a pioneer in phage therapy—the use of viruses (bacteriophages) to attack and destroy antibiotic-resistant bacteria. They are betting on a post-antibiotic era. This chart is a clear indicator of faith in their R&D. It reflects their progress in clinical trials and their ability to overcome complex regulatory hurdles.
AKIMA Market Segment Index - Pharma microbes
Armata Pharmaceuticals develops therapies based on bacteriophages—viruses that selectively destroy antibiotic-resistant bacteria. This chart shows the average index for the pharmaceutical sector. It allows one to assess how Armata's innovative approach to fighting superbugs compares to the average pharmaceutical company.
The AKIM Index for the overall market
Armata Pharmaceuticals is a biotech company developing bacteriophage therapy for the treatment of antibiotic-resistant infections. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this niche scientific enterprise, solving the global superbug problem, compares to overall economic trends.
